Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CONTRACEPTIVE DEVICES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 631 records · Page 35Linked to original sources
PubMed1976

The effect of intra-uterine contraceptive devices on the oestrogen-induced incorporation of [3H-5]uridine into RNA by the rat uterus.

A length of copper or stainless steel wire or of silk thread suture was inserted as an intra-uterine device (IUD) for 3 days in the right uterine horn of ovariectomized virgin female rats. The left horn served as a control. The control rats were ovariectomized but had no IUD inserted. The in vitro incorporation of [3H-5]uridine into uterine RNA was significantly inhibited (P less than 0.005) in copper-bearing horns compared to control horns, while silk and steel devices had no inhibitory effect, thus indicating an effect of intra-uterine copper on oestradiol-induced uterine metabolism. The insertion of an intra-uterine device had no significant effect on uterine wet weight, DNA content or on the uptake of [3H-5]uridine into the nucleotide pool.

Animals↗
PubMed1993

Psoas abscess related to spontaneous abortion, intra-uterine contraceptive device and curettage.

This case report presents a patient with a psoas abscess related to a dilatation and (aspiration) curettage for an incomplete abortion with an IUD. Psoas abscess is extremely rare in obstetrics and gynecology and a life threatening condition. It is important to recognize the clinical presentation. Psoas abscess should be suspected in patients presenting with fever, pain in the leg, thigh, or low back region. Whether antibiotic prophylaxis in abortion curettage may prevent this and other complications is discussed.

Abortion, Incomplete↗
PubMed2004

Clinical outcomes of early postplacental insertion of intrauterine contraceptive devices.

OBJECTIVES: To assess the efficacy, safety and, thus, advantages and disadvantages, of early postplacental intrauterine device (IUD) insertion. METHODS: IUDs were inserted within 10 min after postplacental expulsion in term pregnancy both in vaginal and cesarean deliveries via a ring forceps. Of the 276 patients enrolled, 235 were included in the study. Recipients were scheduled for examination before hospital discharge and at 6 weeks, 6 months and 12 months after postplacental insertion. RESULTS: The percentages of women returning for a follow-up visit were 221 (94%), 210 (89%) and 183 (78%) at 6 weeks, 6 months and 12 months, respectively. Among IUD acceptors, 74% of the cases had vaginal deliveries and 26% had cesarean deliveries. Continuation rates were relatively high, 87.6% and 76.3%, at 6 and 12 months, respectively, after postplacental insertion of IUD. In this study, the 1-year cumulative expulsion rate with TCu 380A device was 12.3%, which may be regarded as a standard expulsion rate for immediate postplacental insertion of similar models of IUDs. CONCLUSION: The evidence from this study suggests that immediate postplacental insertion of CuT 380 models is an effective, useful, safe, convenient and low-cost procedure for early postpartum contraception.

Adult↗
PubMed1986

The intrauterine contraceptive device and hydatidiform mole: a negative association.

None of the 135 hydatidiform moles studied (40 complete and 95 partial) occurred in women currently wearing the IUCD. In the control series of 1,244 non-molar spontaneous abortions, conception took place with the IUCD in situ in 48 women (3.87%). The difference between the observed number of molar pregnancies with the IUCD in situ, i.e., 0, and the "expected" number, i.e., 4.64 (3.87%) was statistically different (p less than 0.05). This difference could not be explained by such uncontrolled confounding variables as maternal age, menstrual age of the abortions, prior pregnancy loss, gravidity, ethnicity or contraceptive practices. It is suggested that the IUCD selectively suppresses the development of molar pregnancies. The theoretical and practical implications of this observation are discussed.

Abortion, Spontaneous↗
PubMed1989

Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.

Levonorgestrel, estradiol and progesterone plasma concentrations were measured over four years of use of a 20 micrograms/day levonorgestrel-releasing intracervical device (LNG-ICD). The mean levonorgestrel concentration showed a slight decline, being 142 + 46 (SD) pg/ml in the third month and 81 +/- 22 pg/ml in the 48th month of LNG-ICD use. However, considerable interindividual variation in levonorgestrel plasma levels between study subjects was observed. In 77% of the monitored cycles, ovulation or a luteinized follicle was observed when judged by a plasma progesterone elevation of over 5 ng/ml. Some follicular function was also noted in anovulatory cycles. Inhibition of ovulatory ovarian function is not the mode of contraceptive action of the LNG-ICD.

Adult↗
PubMed1991

Levels of serum steroid hormones in intrauterine contraceptive device users.

Serum progesterone, estradiol, testosterone and cortisol were assayed in the mid-follicular and mid-luteal phases of the menstrual cycles in 30 Lippe's loop and 30 Cu T-200 IUCD users, compared to 24 controls. Mean serum progesterone and estradiol levels were significantly higher in the mid-luteal, compared to the mid-follicular phase in each group (p less than 0.01). There were no significant differences between the mean levels of progesterone, testosterone and cortisol in IUCD users and controls in both the mid-follicular and mid-luteal phases. IUCD users had significantly higher levels of estradiol (p less than 0.01) in the mid-luteal phase but not in the mid-follicular phase, compared to controls. There was hormonal evidence of corpus luteum insufficiency in 8.3%, 14.3% and 20% in the controls, Lippe's loop and Cu T-200 IUCD users, respectively.

Adolescent↗
PubMed1993

Effect of the intrauterine contraceptive device on protein components of human uterine fluid.

The albumin, immunoglobulin G (IgG), immunoglobulin A (IgA), lysozyme, lactoferrin, alpha 1-antitrypsin, alpha 1x-antichymotrypsin, and neutral proteinase levels of uterine fluid and serum of IUD-bearing women were studied in relationship to the phase of the menstrual cycle, the length of IUD implantation and the presence of reported side effects. Selection of these proteins was based on their potential importance in IUD-induced contraceptive action and/or side effects. Generally, only small differences were found in the serum levels of these proteins during the cycle, with different length of implantation or between patients with and without side effects. However, transudation of proteins (albumin, IgG, alpha 1-antitrypsin, alpha 1x-antichymotrypsin) from blood into the uterine cavity was enhanced by the IUD, especially during the postmenstrual and premenstrual periods. The IUD enhanced the local secretory response even more, i.e., the increased release of proteins from the endometrium (lysozyme, neutral proteinase, IgA) and from leukocytes (lysozyme, lactoferrin). Protein changes occurred as the period of insertion increased. These changes in the uterine milieu may account in part for the contraceptive action of the IUD. The secretory proteins rather than the transudation products differed between patients who showed IUD-associated side effects vs. those who did not, implying that IUD-related pathology is primarily associated with changes in local secretory response. The possible role of each protein in the mechanism of IUD action is presented in view of the present findings.

Adult↗
PubMed1976

[Clinical and morphological studies in patients with a progesterone-releasing intrauterine contraceptive device (Progestasert-System) (author's transl)].

We studied in twenty women the effectiveness of a new type of intrauterine device, which is coated with progesterone. Since the progesterone-coating is estimated to last one year, we studied the women for that period of time. None of them became pregnant. Most complained of some disturbances of menstrual bleeding during the first three months. A few experienced these disturbances for the whole year of observation. No other side effects developed like those experienced with oral contraceptives. Six hysterectomy specimens and one complete curettage became available for us to examine the histological changes produced by this new type of intrauterine device. The endometrium in all revealed a distinct division into two horizontal layers produced by progesterone absorbed from the device. The upper layer of endometrium next to the device showed a decidual change with sparse atrophic glands, like those of an arrested secretion. The underlying layer exhibited either normal proliferative or secretory changes consistent with the phase of the menstrual cycle. The remarkably circumscribed decidual change led us to refer to it as "perifocal arrested secretion", a term emphasizing that the gestagen inserted into the uterine cavity acts locally on the endometrium. Foci of endometrium in the myometrium (adenomyosis) are not affected.

Adolescent↗
PubMed1991

Comparison of immunofluorescence and culture for the detection of Actinomyces israelii in wearers of intra-uterine contraceptive devices.

A direct immunofluorescence (IF) method was compared with traditional culture methods for the detection of Actinomyces israelii in endocervical and intra-uterine-device (IUD) smears from 124 IUD wearers. Of 11 specimens that gave positive results by IF, only one was positive by culture. Of the 10 patients with positive IF specimens, three (30%) had signs and symptoms suggestive of pelvic infection and no other pathogen was detected. Direct IF of cervical smears offers a simple, relatively cheap method to screen IUD wearers for A. israelii. Clinical management of such cases is discussed.

Actinomyces↗
PubMed1982

Puerperal insertion of a copper-releasing and a levonorgestrel-releasing intrauterine contraceptive device.

A copper-releasing IUD and levonorgestrel-releasing IUDs releasing 30 micrograms and 10 micrograms levonorgestrel per day were inserted six weeks after delivery in 110 volunteers. During the treatment, events and patterns of bleeding were recorded and plasma levonorgestrel concentrations were measured. The number of events in one year of follow-up was very low, four removals out of 40 in the copper-releasing IUD group and five removals out of 70 in the levonorgestrel-releasing IUD group. Bleeding and spotting was significantly more common after insertion of a levonorgestrel-releasing IUD than a copper-releasing IUD, but it was scanty and well-tolerated. After three months, levonorgestrel-releasing IUD patients had less bleeding and spotting than the copper-releasing IUD patients. No pregnancies occurred during the study period. There were two uterine perforations with a uterine sound at the insertion. In the 30-micrograms per day levonorgestrel-releasing IUD group, initially high plasma levonorgestrel concentrations reached a plateau four weeks after the insertion. In the 10-micrograms per day levonorgestrel-releasing IUD group, the plasma concentrations of levonorgestrel stabilized after the initial two weeks.

Adult↗